Rodeghiero F, Stasi R, Gernsheimer T, Michel M, Provan D, Arnold DM, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113:2386–93.

Article  CAS  PubMed  Google Scholar 

Matzdorff A, Meyer O, Ostermann H, Kiefel V, Eberl W, Kuhne T, et al. Immune thrombocytopenia—current diagnostics and therapy: recommendations of a joint working group of DGHO, ÖGHO, SGH, GPOH, and DGTI. Oncol Res Treat. 2018;41(Suppl 5):1–30.

Article  PubMed  Google Scholar 

Kurata Y, Fujimura K, Kuwana M, Tomiyama Y, Murata M. Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. Int J Hematol. 2011;93:329–35.

Article  PubMed  Google Scholar 

Terrell DR, Beebe LA, Vesely SK, Neas BR, Segal JB, George JN. The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports. Am J Hematol. 2010;85:174–80.

Article  PubMed  Google Scholar 

Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Provan D, et al. Immune thrombocytopenia (ITP) World Impact Survey (iWISh): patient and physician perceptions of diagnosis, signs and symptoms, and treatment. Am J Hematol. 2021;96:188–98.

Article  CAS  PubMed  Google Scholar 

Provan D, Arnold DM, Bussel JB, Chong BH, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780–817.

Article  PubMed  PubMed Central  Google Scholar 

Kashiwagi H, Kuwana M, Hato T, Takafuta T, Fujimura K, Kurata Y, et al. Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. Int J Hematol. 2020;111:329–51.

Article  PubMed  PubMed Central  Google Scholar 

Singh A, Uzun G, Bakchoul T. Primary immune thrombocytopenia: novel insights into pathophysiology and disease management. J Clin Med. 2021;10:789.

Article  CAS  PubMed  PubMed Central  Google Scholar 

George JN, el-Harake MA, Raskob GE. Chronic idiopathic thrombocytopenic purpura. N Engl J Med. 1994;331:1207–11.

Article  CAS  PubMed  Google Scholar 

Tomiyama Y, Miyakawa Y, Okamoto S, Katsutani S, Kimura A, Okoshi Y, et al. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia. J Thromb Haemost. 2012;10:799–806.

Article  CAS  PubMed  Google Scholar 

Katsutani S, Tomiyama Y, Kimura A, Miyakawa Y, Okamoto S, Okoshi Y, et al. Oral eltrombopag for up to three years is safe and well-tolerated in Japanese patients with previously treated chronic immune thrombocytopenia: an open-label, extension study. Int J Hematol. 2013;98:323–30.

Article  CAS  PubMed  Google Scholar 

Shirasugi Y, Ando K, Miyazaki K, Tomiyama Y, Okamoto S, Kurokawa M, et al. Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial. Int J Hematol. 2011;94:71–80.

Article  CAS  PubMed  Google Scholar 

Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237–47.

Article  CAS  PubMed  Google Scholar 

Kuter DJ, Rummel M, Boccia R, Macik BG, Pabinger I, Selleslag D, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010;363:1889–99.

Article  CAS  PubMed  Google Scholar 

Pharmaceuticals and Medical Devices Agency. Revolade (eltrombopag) report on the deliberation results. 2010.

Pharmaceuticals and Medical Devices Agency. Romiplate (romiplostim) report on the deliberation results. 2011.

Cooper N, Scully M, Percy C, Nicolson PLR, Lowe G, Bagot CN, et al. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: results from the TRAIT study. Br J Haematol. 2024;204:2442–52.

Article  CAS  PubMed  Google Scholar 

United States Food and Drug Administration. Promacta (eltrombopag) US prescribing information. 2020.

European Medicines Agency. Revolade (eltrombopag) summary of product characteristics. 2022.

Jansen AJG, McDonald V, Newland A, Morgan M, Bastiaanse M, Wilson K, et al. Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in The Netherlands (TRAPeze Netherlands study). Hematology. 2023;28:2267942.

Article  PubMed  Google Scholar 

Lucchesi A, Lovrencic B, McDonald V, Newland A, Morgan M, Eriksson D, et al. Treatment preferences towards thrombopoietin-receptor agonists for immune thrombocytopenia and experience of disease (TRAPeze): Italy cohort. Hematology. 2023;28:2253069.

Article  PubMed  Google Scholar 

McDonald V, Newland A, Morgan M, Wilson K, Nazir J, Maguire P, et al. Patient preferences and experiences regarding thrombopoietin-receptor agonists for immune thrombocytopenia in the United Kingdom and Ireland (TRAPeze UK & IE study). Hematology. 2021;26:799–808.

Article  CAS  PubMed  Google Scholar 

Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Wojdyla M, et al. Adults with immune thrombocytopenia who switched to avatrombopag following prior treatment with eltrombopag or romiplostim: a multicentre US study. Br J Haematol. 2022;197:359–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kuter DJ, Allen LF. Avatrombopag, an oral thrombopoietin receptor agonist: results of two double-blind, dose-rising, placebo-controlled Phase 1 studies. Br J Haematol. 2018;183:466–78.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bussel JB, Kuter DJ, Aledort LM, Kessler CM, Cuker A, Pendergrass KB, et al. A randomized trial of avatrombopag, an investigational thrombopoietin-receptor agonist, in persistent and chronic immune thrombocytopenia. Blood. 2014;123:3887–94.

Article  CAS  PubMed  Google Scholar 

Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183:479–90.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mei H, Zhou H, Hou M, Sun J, Zhang L, Luo J, et al. Avatrombopag for adult chronic primary immune thrombocytopenia: a randomized phase 3 trial in China. Res Pract Thromb Haemost. 2023;7: 102158.

Article  CAS  PubMed  PubMed Central  Google Scholar 

United States Food and Drug Administration. Doptelet (avatrombopag): highlights of prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/210238s009lbl.pdf. Accessed.

European Medicines Agency. Doptelet (avatrombopag): summary of product characteristics. 2024.

National Medical Products Administration. Avatrombopag Product Information. 2020.

Dova Pharmaceuticals. China National Medical Products Administration Approves DOPTELET® (avatrombopag) for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. 2020.

Pharmaceuticals and Medical Devices Agency. New Drugs Approved in FY 2022. 2022.

Nomoto M, Pastino G, Rege B, Aluri J, Ferry J, Han D. Pharmacokinetics, pharmacodynamics, pharmacogenomics, safety, and tolerability of avatrombopag in healthy Japanese and white subjects. Clin Pharmacol Drug Dev. 2018;7:188–95.

Article  CAS  PubMed  Google Scholar 

Jain S, Gernsheimer T, Kolodny S, Bernheisel C, Vredenburg M, Panch SR. Additional efficacy analysis of avatrombopag phase III data for the treatment of adults with immune thrombocytopenia. Platelets. 2023;34:2195016.

Article  PubMed  Google Scholar 

Al-Samkari H, Jiang D, Gernsheimer T, Liebman H, Lee S, Bernheisel C, et al. Durability of platelet response after switching to avatrombopag from eltrombopag or romiplostim in immune thrombocytopenia. Res Pract Thromb Haemost. 2023;7: 100134.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Neunert C, Terrell DR, Arnold DM, Buchanan G, Cines DB, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829–66.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Segal JB, Powe NR. Prevalence of immune thrombocytopenia: analyses of administrative data. J Thromb Haemost. 2006;4:2377–83.

Article  CAS  PubMed